---
title: "Cybin  GAAP EPS of -$1.00 misses by $0.41"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275902310.md"
description: "Cybin GAAP EPS of -$1.00 misses by $0.41"
datetime: "2026-02-13T12:47:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275902310.md)
  - [en](https://longbridge.com/en/news/275902310.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275902310.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275902310.md) | [繁體中文](https://longbridge.com/zh-HK/news/275902310.md)


# Cybin  GAAP EPS of -$1.00 misses by $0.41


### Related Stocks

- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Cybin Inc. (HELP.US)](https://longbridge.com/en/quote/HELP.US.md)
- [Cybin Inc. (CYBN.US)](https://longbridge.com/en/quote/CYBN.US.md)
- [Cyclerion Therapeutics, Inc. (CYCN.US)](https://longbridge.com/en/quote/CYCN.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Cybin’s Helus Pharma Posts Strong Phase 2 Data for HLP004 in Hard-to-Treat Anxiety](https://longbridge.com/en/news/277946472.md)
- [Veeva Systems Q4 revenue eases past estimates](https://longbridge.com/en/news/277834275.md)
- [Bioventus beats Q4 revenue estimates on strong demand for pain treatments and surgical solutions](https://longbridge.com/en/news/277932436.md)
- [Craig-Hallum Sticks to Their Buy Rating for Apogee Therapeutics (APGE)](https://longbridge.com/en/news/277492684.md)
- [Immuneering posts smaller‑than‑expected Q4 loss on reduced R&D costs](https://longbridge.com/en/news/278102320.md)